A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)
Asthma

About this trial
This is an interventional treatment trial for Asthma
Eligibility Criteria
Inclusion Criteria:
- Male or female between the ages of 18 and 65
- Must have mild or moderate asthma (Part III only)
- Nonsmoker for at least 6 months
Exclusion Criteria:
- History of stroke, chronic seizures or major neurological disorder
- You are nursing
- Drink more than 3 glasses of alcohol a day
- Have allergy to or not able to tolerate lactose
- Have a history of drug abuse in the last 5 years
- Drink more than 6 beverages containing caffeine a day
- Have had surgery, donated blood or participated in another investigational study in the last 4 weeks
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
Montelukast 0.1 mg
Montelukast 0.3 mg
Montelukast 1 mg
Montelukast 3 mg
Montelukast 10 mg
Placebo
Participants receive Montelukast inhalation powder, 0.1 mg. Part I: Administered as a single dose followed by at least a 3-day washout period.
Participants receive Montelukast inhalation powder, 0.3 mg. Part I: Administered as a single dose followed by at least a 3-day washout period.
Participants receive Montelukast inhalation powder, 1 mg. Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered once daily (QD) for 5 days followed by at least a 3-day washout period.
Participants receive Montelukast inhalation powder, 3 mg. Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered QD for 5 days followed by at least a 3-day washout period. Part III: Administered QD for 10 days followed by at least a 7-day washout period.
Participants receive Montelukast inhalation powder, 10 mg. Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered QD for 5 days followed by at least a 3-day washout period. Part III: Administered QD for 10 days followed by at least a 7-day washout period.
Participants receive Placebo to Montelukast inhalation powder. Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered QD for 5 days followed by at least a 3-day washout period. Part III: Administered QD for 10 days followed by at least a 7-day washout period.